VERA Vera Therapeutics
- 36.020
- -1.380-3.69%
- 36.020
- 0.0000.00%
Vera Therapeutics News
Express News | Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on June 4, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday.Shares of Stericycle, Inc. (NASDAQ:SRCL) rose sharply during Monday's session after the company inked a deal to be
Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady in April: This Week in the Market
The U.S. stock market ended a five-week positive streak as investors feared that slowing economic momentum could impact the earnings outlook for American corporations.
Express News | JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $65
Express News | Vera Therapeutics Inc : JP Morgan Raises Target Price to $65 From $60
Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
NVIDIA has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking.
Express News | Vera Therapeutics Shares Are Trading Higher After the Company Received FDA Breakthrough Therapy Designation for Atacicept
Express News | Vera Therapeutics Inc - First Half of 2025 We Expect Primary Endpoint Results From Our Pivotal Phase 3 Origin 3 Trial
Express News | Vera Therapeutics- Plan to Announce Long-Term 96-Week Results From Phase 2B Origin Trial Later This Year
Express News | Vera Therapeutics Receives FDA Breakthrough Therapy Designation For Atacicept In IgAN
Express News | Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin a Nephropathy (Igan)
Express News | Reported Saturday, Vera Therapeutics Presented 72-week EGFR Stabilization And Rapid Hematuria Improvement In Phase 2b ORIGIN Study Of Atacicept In IgAN At The 61st European Renal Association Congress
Express News | Vera Therapeutics - Look Forward to Presenting Full 96-Week Data From Phase 2B Origin Trial, Which Are Expected in the Fourth Quarter of This Year
Express News | Vera Therapeutics - Rapid Improvements in Hematuria Over 36 Weeks, With Resolution in Significantly Greater Percentage of Participants Than Placebo
Express News | Vera Therapeutics - 72-Week Data Consistent With Disease Modification in Igan, Selected as a Best-Ranked Abstract
Express News | Vera Therapeutics Presents 72-Week Egfr Stabilization and Rapid Hematuria Improvement in Phase 2B Origin Study of Atacicept in Igan at the 61St European Renal Association Congress
Vera Therapeutics Presents 72-week EGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract;Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater percentage of
Vera Therapeutics(VERA.US) Officer Sells US$1.3 Million in Common Stock
$Vera Therapeutics(VERA.US)$ Officer Young Joseph R sold 30,837 shares of common stock on May 15, 16, 2024 at an average price of $42.301 for a total value of $1.3 million.Source: Announcement What is
Analysis
Price Target
No Data
